0000000000072865

AUTHOR

J.a. Pons

showing 2 related works from this author

Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach

2012

A sustained virological response (SVR) is achieved by 30% of naive liver transplantation (LT) recipients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Almost no data are available about retreatment. The aim of this study was to assess the efficacy, tolerability, and SVR predictors of retreatment. Data were collected from 4 centers on the retreatment of prior nonresponders to standard therapy or PEG-IFN (with or without RBV) and relapsers. Seventy-nine of 301 treatment-experienced LT patients (26%), who had a median age of 59 years (range = 35-77 years) and were mostly male (72%) and infected with genotype 1 (87%), were retreated with PEG-IFN and RBV at a median of 6.9 yea…

Transplantationmedicine.medical_specialtyCirrhosisHepatologybusiness.industryRibavirinmedicine.medical_treatmentHepatitis C virusLiver transplantationmedicine.diseasemedicine.disease_causeGastroenterologyTacrolimusSurgerychemistry.chemical_compoundchemistryTolerabilityErythropoietinPegylated interferonInternal medicinemedicineSurgerybusinessmedicine.drugLiver Transplantation
researchProduct

Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

2012

AdultPathologymedicine.medical_specialtyBiopsymedicine.medical_treatmentLiver transplantationEnd Stage Liver DiseaseRecurrenceBiopsyAnimalsHumansMedicineAntilymphocyte SerumClinical Trials as TopicTransplantationHepatologymedicine.diagnostic_testbusiness.industryCase-control studyEnd stage liver diseaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationAnti-thymocyte globulinCase-Control StudiesImmunologySurgeryRabbitsbusinessImmunosuppressive AgentsLiver Transplantation
researchProduct